Home/ Stocks/ ACET

Adicet Bio, Inc. Common Stock

ACET XNAS

$8.06 +0.27 (+3.47%) ▲ 15-min delayed

Open

$7.84

High

$8.26

Low

$7.74

Volume

107.9K

Market Cap

$72.82M

About Adicet Bio, Inc. Common Stock

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 102 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-20,244,000	$-1.88
FY 2025	$0	$-116,803,000	$-16.95
Q3 2025	$0	$-26,856,000	$-0.29
Q2 2025	$0	$-31,217,000	$-0.34

Related Market News

No specific coverage for ACET yet. Check out our latest market news or earnings calendar.

Get ACET Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Adicet Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.